---
title: "Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality"
description: "Merck & Co., Inc. (NYSE:MRK) reported strong earnings, but its stock price remained stable. Analysts suggest that unusual expenses of US$4.2 billion may not recur, indicating potential profit growth. "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252716610.md"
published_at: "2025-08-12T16:15:38.000Z"
---

# Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

> Merck & Co., Inc. (NYSE:MRK) reported strong earnings, but its stock price remained stable. Analysts suggest that unusual expenses of US$4.2 billion may not recur, indicating potential profit growth. Merck's earnings per share rose by 20% last year, and future profitability looks promising. However, there is one warning sign to consider. Investors are encouraged to explore further details about Merck's financial health and risks.

Explore Merck's Fair Values from the Community and select yours

**Merck & Co., Inc.** (NYSE:MRK) just reported healthy earnings but the stock price didn't move much. Our analysis suggests that investors might be missing some promising details.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

## The Impact Of Unusual Items On Profit

To properly understand Merck's profit results, we need to consider the US$4.2b expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If Merck doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

## Our Take On Merck's Profit Performance

Because unusual items detracted from Merck's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Merck's earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share increased by 20% in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Merck as a business, it's important to be aware of any risks it's facing. While conducting our analysis, we found that Merck has **1 warning sign** and it would be unwise to ignore it.

Today we've zoomed in on a single data point to better understand the nature of Merck's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this **free** collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 默克執行副總裁兼總法律顧問 Jennifer Zachary 報告出售普通股 | 梅克公司（Merck & Co. Inc.）執行副總裁兼總法律顧問 Jennifer Zachary 報告了該公司普通股的處置。完整的文件可以通過提供的鏈接訪問。此新聞簡報由公共技術公司生成，僅供信息參考，不應被視為財務、投資或法律建議。梅 | [Link](https://longbridge.com/en/news/275360987.md) |
| 默克獲得 FDA 批准，Keytruda 聯合療法用於治療卵巢癌 | 默沙東已獲得 FDA 批准，將 Keytruda 和 Keytruda Qlex 與紫杉醇聯合用於治療鉑耐藥性卵巢癌。該批准基於 III 期 KEYNOTE-B96 試驗數據，顯示 PD-L1 表達腫瘤患者在無進展生存期和總體生存期方面有顯 | [Link](https://longbridge.com/en/news/275742611.md) |
| 索羅斯逆市加碼微軟及 Nvidia 等科企 新買入黃金股 清倉 4 隻股份 | 索羅斯基金管理公司在 2022 年第四季度加大對微軟、英偉達和蘋果等大型科技股的投資，同時增持黃金股以對衝風險。基金還增持了 Atlassian、Salesforce 和 Uber 等軟體公司股票，但大幅減持了 Snowflake 和 Ci | [Link](https://longbridge.com/en/news/275990619.md) |
| 每千次展示 60 美元！OpenAI 用高價拉開 “AI 廣告” 大幕 | 為應對 AI 鉅額開支，OpenAI 正式測試廣告，CPM60 美元起步、最低投入 20 萬美元，定位高端渠道，直接挑戰谷歌萬億美元市場，WPP 等頂級代理已率先合作。但轉型風險並存：需平衡用户信任，承諾不用私聊數據；對手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| 伊本·阿爾·海賽姆醫院全年收入為 301,281 第納爾 | 伊本·海瑟姆醫院公司 PSC (IBNH.AM)：伊本·海瑟姆醫院財年税後淨收入為 301,281 第納爾；伊本·海瑟姆醫院財年收入為 1210 萬第納爾 | [Link](https://longbridge.com/en/news/275996849.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.